Surgery versus SABR for resectable non-small-celllung cancer - Authors' reply

The Lancet Oncology

Volumn 16, Issue 8, 2015, Pages e374-e375

  Chang, Joe Y ^a   Senan, Suresh ^b   Smit, Egbert F ^b   Roth, Jack A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; CANCER STAGING; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; LETTER; LUNG LOBECTOMY; LUNG SURGERY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC TREATMENT; VIDEO ASSISTED THORACOSCOPIC SURGERY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOSURGERY; TEMPORAL LOBECTOMY;

ANTERIOR TEMPORAL LOBECTOMY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOSURGERY;

EID: 84938054002     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00154-0     Document Type: Letter

References (11)

1. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015, 16:630-637.
2. Herder GJ, van TH, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest 2005, 128:2490-2496.
3. Pisu M, Kenzik KM, Oster RA, et al. Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer?. Cancer 2015, 121:1257-1264.
4. Rajaram R, Ju MH, Bilimoria KY, Ko CY, DeCamp MM National evaluation of hospital readmission after pulmonary resection. J Thorac Cardiovasc Surg 2015, published online May 21. 10.1016/j.jtcvs.2015.05.047.
5. Licht PB, Jørgensen OD, Ladegaard L, Jakobsen E A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer. Ann Thorac Surg 2013, 96:943-949.
6. Boffa DJ, Kosinski AS, Paul S, Mitchell JD, Onaitis M Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. Ann Thorac Surg 2012, 94:347-353.
7. Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol 2013, 24:1543-1548.
8. Pezzi CM, Mallin K, Mendez AS, et al. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg 2014, 148:2269-2278.
9. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011, 141:662-670.
10. Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol 2015, 114:138-147.
11. Taylor MD, LaPar DJ, Isbell JM, Kozower BD, Lau CL, Jones DR Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2014, 147:738-744.